Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Objective:</b> Our aim is to study the prognostic value of stem cell markers (CD44, Nestin, Olig2 and SOX2) in a series of homogeneously treated GBs.
|
31496301 |
2019 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results also showed that metformin significantly suppressed self-renewal capacity of glioblastoma stem cells (GSCs), and expression of stem cell markers Bmi1, Sox2 and Musashi1, indicating that metformin can inhibit cancer stem-like properties of GBM cells.
|
29467947 |
2018 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inhibition of switch genes highly correlates with the activation of genes related to neural development and differentiation, such as the 4-core OLIG2, POU3F2, SALL2, SOX2, whose induction has been shown to be sufficient to reprogram differentiated glioblastoma into stem-like cells.
|
30497369 |
2018 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When HSF1 or BIS knockdown was combined with temozolomide (TMZ) treatment, a standard drug used in glioblastoma therapy, apoptosis increased, as measured by an increase in poly (ADP-ribose) polymerase (PARP) cleavage, whereas cancer stem-like properties, such as colony-forming activity and SOX2 protein expression, decreased.
|
28241425 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Penfluridol treatment suppressed the phosphorylation of Akt at Ser473 and reduced the expression of GLI1, OCT4, Nanog and Sox2 in several glioblastoma cell lines in a concentration-dependent manner.
|
28380428 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Elevated FOXG1 and SOX2 in glioblastoma enforces neural stem cell identity through transcriptional control of cell cycle and epigenetic regulators.
|
28465359 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Embryonic stem cell factors-OCT4, NANOG, and SOX2-contribute to the maintenance of stem cell properties and malignant progression in various cancers, including glioblastoma.
|
28933914 |
2017 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells.
|
27530866 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Epigenetic modulation of a miR-296-5p:HMGA1 axis regulates Sox2 expression and glioblastoma stem cells.
|
26898758 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
SOX2 and SOX9 expression correlates positively in glioma cells and glioblastoma biopsies.
|
26878385 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD9 silencing in three CD133+ glioblastoma cell lines (NCH644, NCH421k and NCH660h) led to decreased cell proliferation, survival, invasion, and self-renewal ability, and altered expression of the stem-cell markers CD133, nestin and SOX2.
|
26573230 |
2016 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of G9a also increased Sox2 protein levels in another ER(+) breast cancer cell line, ZR-75-1, whereas it did not affect Sox2 expression in MDA-MB-231 cells, an ER(-) breast cancer cell line, or in glioblastoma cell lines.
|
26492085 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.
|
26074073 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2.
|
26444992 |
2015 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Enhancement of SOX-2 expression and ROS accumulation by culture of A172 glioblastoma cells under non-adherent culture conditions.
|
26035068 |
2015 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacological blockade with SR48692 or lentivirus mediated knockdown of NTSR1 efficiently reduced the sphere-forming ability and expression of stem cell markers such as nestin and Sox2 in GSCs isolated from glioblastoma cell line and glioblastoma tissues.
|
25200966 |
2014 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sox2 promotes malignancy in glioblastoma by regulating plasticity and astrocytic differentiation.
|
24726753 |
2014 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Double immunostaining for FABP7 and Sox2 showed that FABP7(+) Sox2(+) tumor cells were significantly increased in glioblastoma (grade IV) compared with diffuse astrocytoma (grade II) and anaplastic astrocytoma (grade III).
|
24274717 |
2013 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We provide evidence that sorafenib has a selective action on glioblastoma stem cells, causing enrichment of cultures in differentiated cells, downregulation of the expression of stemness markers required to maintain malignancy (nestin, Olig2 and Sox2) and reducing cell clonogenic ability in vitro and tumorigenic potential in vivo.
|
23324350 |
2013 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells.
|
22937156 |
2012 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription factor Sox2, a key gene implicated in maintaining the "stemness" of embryonic and adult stem cells, plays an important role in the carcinogenesis and maintenance of glioblastoma.
|
21703238 |
2011 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study thus describes a tumor- and neurosphere-forming SOX2-dependent subset of glioblastoma cultures characterized by a gene expression signature similar to that of the recently described classical, proneural, and/or neural subsets of glioblastoma.
|
21940738 |
2011 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In our previous work we detected SOX2 in glioma cells and glioblastoma specimens.
|
22070920 |
2011 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
SOX2, or its immediate downstream effectors, would then be an ideal target for glioblastoma therapy.
|
18948646 |
2009 |